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ABSTRACT
Objectives: Gestational diabetes mellitus (GDM) is carbohydrate intolerance that occurs during pregnancy.
The present study was arranged to determine the risk of cerebral ischemia (CI) in infants born to mothers
with gestational diabetes mellitus and MTHFR gene polymorphism.
Material and methods: The study includes 70 pregnant women with GDM, divided into two groups
depending on existence of cerebral ischemia (CI) in newborn infants. All patients were tested for coagula-
tion cascade components, polymorphisms of the methylenetetrahydrofolate reductase (MTHFR) gene and
assessed by thromboelastography (TEG).
Results: We observed that there was an increased frequency (74.2%) of 1298 MTHFR genotype carriers
among women with CI newborns. The state of hypercoagulation according to both coagulation cascade
tests and TEG data was diagnosed in women of this group.
Conclusions: The results of this study suggest that hyperglycemia may program the development of cere-
bral ischemia in infants born to women with 1298 MTHFR gene polymorphism.
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Introduction
Gestational diabetes mellitus (GDM) is a frequently encountered
condition during pregnancy which is related to insulin resistance
and inadequate insulin secretion at hyperglycemia. According to
the International Diabetic Federation, 20.9 millions (16.2%)
infants were born in the world in 2015 to the mothers with
GDM or mothers affected by other forms of hyperglycemia [1].
There is a significant concordance in observed incidence of
GDM, metabolic syndrome and obesity in the modern popula-
tion of pregnant women [2,3].
Impact of diabetes on the coagulation system and endothelial
functions is known for many years. Hemostatic factors and activ-
ities are influenced by the hyperglycemic state. Moreover, preg-
nancy induces a hypercoagulable state as a physiological
mechanism to ensure the hemostatic balance by preventing mas-
sive maternal blood loss at delivery [4].
It is important to recognize and monitor GDM tightly due to
the risk of adverse effects on the mother and the fetus such as
development of preeclampsia, placental insufficiency, prematurity
and necessity for cesarean section and its association to birth
injuries [5],
High risk of metabolic disturbances, respiratory distress syn-
drome and neurological injuries was demonstrated in infants
born to mothers with GDM. These adverse effects could persist
in these infants during a later life [6].
Most of the perinatal neurological injuries (intraventricular
hemorrhage, cerebral ischemia) could be considered as a complex
developmental disorders, with contributions from both the envir-
onment and the gene. It was demonstrated that polymorphisms
in methylenetetra-hydrofolate reductase (MTHFR) gene are
associated with neonatal cerebral injuries in the presence of peri-
natal hypoxia [7].
Considering the impact of GDM on the coagulation system
and placental oxygen transport the influence of gene polymor-
phisms on the fetus and newborn infant remain still unclear. The
objective of the study was to determine the risk of cerebral ische-
mia in infants born to mothers with gestational diabetes mellitus
and MTHFR gene polymorphism.
Methods
Recruitment of subjects
A total of 70 subjects were recruited (2011–2016) and gave their
informed consent at admission to labor and delivery at Maternity
and Child Care Research Institute (Yekaterinburg, Russia) as a
part of ongoing investigation of gestational diabetes approved by
the institutional ethics committee.
According to the International Association of Diabetes and
Pregnancy Study Groups (IADPSG) criteria [8], irrespective of
gestational age, the diagnosis of GDM during pregnancy is
made on the basis of fasting glucose 126mg/dL; glucose
200mg/dL, measured 2 h after a 75 g glucose oral load; or a
random blood glucose level 200mg/dL, associated with clin-
ical symptoms.
Fasting glucose values of 92–125mg/dL or glucose levels of
153–199mg/dL, measured 2 h after a 75 g glucose load, were used
to confirm the diagnosis of GDM [9].
Exclusion criteria for this study were: type-1 and type-2 dia-
betes, autoimmune and inflammatory diseases, maternal or fetal
infections and fetal congenital anomaly.
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All women were treated with diet control alone throughout
the pregnancy. All newborn infants were consulted by pediatric
neurologist within 3 days after birth and brain ultrasound investi-
gations were performed using Philips HD 15 (Philips Medical
Systems, USA) ultrasound machine with 5MHz probe.
Women with GDM were divided into two groups depending
on existence of cerebral ischemia (CI) in newborn infants. First
(main) group contains 31 women delivered infants with CI, 2d
(control) group contains 39 women who delivered infants with-
out CI.
Standard coagulation tests were monitored for each patient
before the labor or cesarean delivery. Whole venous blood speci-
mens (3.0ml) were collected into vials containing 0.3ml of 3.2%
sodium citrate. One milliliter of blood was removed for thrombo-
lastography (TEG) analysis while the reminder was used for clin-
ically indicated PTT and fibrinogen assays. TEG determinations
were performed on Helena AC-4 analyzer (Helena Bioscience
Europe, UK) according to the manufacturer’s instruction.
The four variables directly measured were: (1) Clotting Time
(R): the time of latency until initial fibrin formation, (2) Clot
Kinetics (K): the speed at which a specific level of clot strength is
achieved (20mm amplitude), (3) Angle (a): the rapidity of clot
strengthening and (4) Maximum Amplitude (MA): the ultimate
strength of the clot. Additionally, a coagulation index (CI) was
derived from the four directly measured variables. Finally, the
LY30 measures the rate at which amplitude decreases 30min
after MA is achieved and is representative of clot breakdown or
fibrinolysis. Also standard tests, including partial thromboplastin
time (PTT), international normalized ratio (INR), thrombin time
(TB), fibrinogen concentration and fibrinolytic activity (FA) to
assess the coagulation cascade effectiveness were performed.
Maternal buccal epithelium samples were genotyped using real-
time PCR by DT-96 equipment, kits and manuals of DNA
Technology (DNA Technology, Russia).
Statistical analysis
The agreement of the genotype distribution with the
Hardy–Weinberg equilibrium was assessed using the exact test. A
chi-square test was used to compare genotype and allele distribu-
tion between groups. Coagulation parameters were compared
between genotype groups using the Mann-Whitney test.
Statistical significance was assessed at the value of p< .05.
Results
Maternal and neonatal clinical parameters for both studied
groups are shown in Table 1. The two groups were not different
for maternal age, parity, maternal BMI and incidence of
cesarean delivery. However, mean neonatal birth weight was sig-
nificantly less in 1st group than in 2d group. Also significant dif-
ference was demonstrated for 1min and 5min Apgar scores
between two groups.
We have analyzed the frequency of determination of the geno-
type which contain the “risk” alleles according to the polymorph-
ous locuses of genes which are coding the coagulation cascade
proteins F5:1691G>A, F2: 20210G>A, FGB: 455G>A, PAI-1:
5 G> 4G, ITGA2: 807C  T, ITGB3 1565T  C, MTR
2756A>G, MTRR 66A>G, MTHFR 677> b MTHFR
1298A>C.
We observed that there was an increased frequency (74.2%) of
genotype MTHFR with polymorphism 1298A>C. Variant allele
1298C in homo- and heterozygote state was found in all women
of the first group. In all women of 2d group the genotype
MTHFR 1298ffff was determined.
The coagulation data in women of both studied groups pre-
sented in Table 2.
Clotting tests reveal the state of hypercoagulation in women
of the 1st group with allele 1298 MTHFR gene in comparison
with women of group 2. The increase in fibrinogen content
(6.09 ± 0.11 g/l vs 5.77 ± 0.19 g/l) was shown in women of group
1. In these women the activation of the internal coagulation cas-
cade was determined (PTT was 28.4 ± 0.4 s. vs. 31.0 ± 0.5 s in
group 2). There was also a significant inhibition of serum fibri-
nolitic activity in women of 1st group (Table 2).
The structural and kinetic characteristics of clot formation
according to TEG results were increased in women of 1st group.
Both R and K indexes were significantly decreased in women of
this group (Table 2) which means the increase the clot formation
speed in women with polymorphous allele 1298 MTHFR gene.
Also both a angle and clot maximal amplitude were increased in
women of 1st group. These changes in TEG parameters resulted
in the significant increase in coagulation index (3.4 ± 0.2 in
women of 1st group versus 2.5 ± 0.2 in women of 2d group).
Discussion
Production and activation of prothrombotic and fibrinolytic fac-
tors are balanced very well in normal pregnancy. It was shown
that plasma levels of clotting factors, such as fibrinogen and
some other factors, increase while fibrinolysis is inhibited due to
the compact structure and innate resistance of the fibrin mol-
ecule to lysis in diabetes mellitus [10]. GDM may be quite similar
to a milder form of the metabolic syndrome. Since body mass is
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Table 1. Clinical and demographic characteristics of study population.
Parameters
Group 1
(MTHFR: 1298/)
(n¼ 31)
Group 2
(MTHFR: 1298ffff)
(n¼ 39)
Maternal age (years) 31.8 ± 1.3 32.1 ± 1.4
Parity 2.0 ± 1.2 1.9 ± 1.1
BMI before pregnancy 23.5 ± 1.3 24.6 ± 0.9
BMI at pregnancy 27.2 ± 1.2 28.2 ± 0.8
Neonatal birth weight 2432.6 ± 458.8 3521.7 ± 352.1
Gestational age (wk) 37.2 ± 1.1 38.3 ± 1.3
Cesarian delivery (n,%) 15 (48%) 18 (46%)
Apgar at 1st min 5.3 ± 0.6 7.8 ± 0.4
Apgar at 5th min 6.3 ± 0.7 8.4 ± 0.5
Statistical significance p< .05.
Table 2. Parameters of TEG and coagulation cascade in women of studied
groups.
Parameters
Group 1
(MTHFR: 1298/)
(n¼ 31)
Group 2
(MTHFR: 1298ffff)
(n¼ 39)
Coagulation cascade
Fibrinogen, g/l 6.09 ± 0.11 5.77 ± 0.19
FA, min 32.72 ± 1.28 34.31 ± 3.83
ffl, sec 15.4 ± 0.2 15.5 ± 0.2
PTT, sec 28.4 ± 0.4 31.0 ± 0.5
INR, % 0.99 ± 0.01 0.99 ± 0.01
Thrombolastography
R, min 7.40 ± 0.19 7.75 ± 0.23
K, min 1.2 ± 0.1 1.8 ± 0.1
a, deg 67.5 ± 0.9 64.9 ± 1.2
MA, mm 69.3 ± 1.0 66.2 ± 1.1
E 234.2 ± 7.4 201.8 ± 10.9
CI 3.4 ± 0.2 2.5 ± 0.2
LY30, % 0.9 ± 0.2 0.9 ± 0.5
Statistical significance p< .05.
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higher in women with GDM compared to healthy women, insu-
lin resistance may be triggered in pregnant subjects leading to
gestational diabetes.
One of the most important measures in assessing the coagula-
tion cascade is PTT. There are studies showing that decreased
PTT support hypercoagulability status in both normal pregnancy
and GDM [11]. It was determined that PTT and platelet counts
were significantly lower in the 3rd trimester of normal pregnancy
[12]. However, another group reported that both parameters
were unchanged in women with GDM [13]. In our findings, PTT
was lower in 1st group than in 2d. We think that this data sup-
port hypercoagulable state in GDM. Moreover, there was no
compensatory increase in fibrinolitic activity in women of the
first group with allele 1298 MTHFR gene.
We found that mean birth weight of infants born to GDM
mothers with polymorphous MTHFR gene was less than in neo-
nates of 2d group women. One could suggest some degree of pla-
cental dysfunction as a result of coagulation disturbances in
women of the first group.
In this study, we examined the association between MTHFR
gene polymorphism in GDM women and cerebral ischemia of
their newborn infants. Our results have indicated increased fre-
quency of CI and 1298 MTHFR allele genotype among women
with GDM. Maternal MTHFR gene mutation has a significant
impact on offspring. It was reported that homozygosity mutation
in the MTHFR gene was associated with increased frequency of
fetal growth retardation and neonatal brain injuries [14].
There is a hypothesis that neonatal cerebral injuries are sec-
ondary to the interaction of the epigenetic stimuli and genome
[15]. The epigenetic programing is active during pregnancy, and
epigenetic processes respond to environmental stimuli ranging
from maternal nutritional restriction to hypoxia and hypergly-
cemia [16].
Therefore, the genetic predisposition (polymorphous allele
1298 MTHFR gene) may represents a potential risk factor for
cerebral ischemia in newborn infants born to mothers with gesta-
tional diabetes mellitus.
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